Difference between revisions of "Sutimlimab (Enjaymo)"
Jump to navigation
Jump to search
m (Jwarner moved page Sutimlimab (BIVV009) to Sutimlimab (Enjaymo): FDA approval) |
|||
Line 4: | Line 4: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
*[[Cold agglutinin disease]] | *[[Cold agglutinin disease]] | ||
− | |||
− | |||
==History of changes in FDA indication== | ==History of changes in FDA indication== |
Revision as of 10:33, 5 November 2022
Mechanism of action
Anti-C1s antibody
Diseases for which it is used
History of changes in FDA indication
- 2/4/2022: Approved to decrease the need for red blood cell transfusion due to hemolysis (red blood cell destruction) in adults with cold agglutinin disease (CAD). (Based on CARDINAL)
Also known as
- Code name: BIVV009
- Generic name: sutimlimab-jome
- Brand name: Enjaymo